Chemical formula: C₂₁H₁₈F₃N₃O₅ Molecular mass: 449.386 g/mol PubChem compound: 90311989
Bictegravir interacts in the following cases:
Bictegravir is both a P-gp and a BCRP substrate. The clinical relevance of this feature is not established. Therefore, caution is recommended when bictegravir is combined with medicinal products known to inhibit P-gp and/or BCRP (e.g. macrolides, ciclosporin, verapamil, dronedarone, glecaprevir/pibrentasvir).
There are no or limited data (less than 300 pregnancy outcomes) from the use of bictegravir in pregnant women.
Studies of bictegravir in animals have shown no evidence of harmful effects on fertility parameters, pregnancy, or foetal development.
Bictegravir should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
It is not known whether bictegravir is excreted in human milk. In animal studies, bictegravir was detected in the plasma of nursing rat pups likely due to the presence of bictegravir in milk, without effects on nursing pups.
There is insufficient information on the effects in newborns/infants, therefore bictegravir should not be used during breast-feeding.
No human data on the effect of bictegravir on fertility are available. Animal studies indicate no effects of bictegravir on mating or fertility.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
